Pulse Biosciences names Maria Sainz to board of directors

Pulse Biosciences Inc. (NASDAQ: PLSE) appointed Maria Sainz to its board of directors effective January 9, 2026, according to a company statement.

Sainz brings more than 30 years of healthcare technology experience, including 18 years in chief executive roles at publicly traded companies and venture-backed startups. She currently serves as president and CEO of Hyperfine Inc. (NASDAQ: HYPR), a medical technology company with a portable brain MRI system.

Previously, Sainz held CEO positions at Aegea Medical, CardioKinetix Inc., and Concentric Medical. She also served in leadership roles at Guidant Corporation and Boston Scientific Corporation, including as president of the Cardiac Surgery Division and vice president of Global Marketing for Vascular Intervention.

Sainz has served on boards of several companies including Shockwave Medical (NASDAQ: SWAV), Spectranetics Corp (NASDAQ: SPNC), Avanos Medical (NASDAQ: AVNS), and Orthofix Medical Inc (NASDAQ: OFIX). She holds a Master of English from Complutense University of Madrid and a Master of International Management from Thunderbird School of Global Management.

Pulse Biosciences develops nanosecond pulsed field ablation technology for medical applications. The company is pursuing development of its nPulse technology for treating atrial fibrillation and surgical soft tissue ablation.

You May Also Be Interested In

• Shopify board member resigns to join U.S. Department of Commerce
• Employers Holdings adds former Hartford executive to its board
• Ampli Technologies adds Verbit founder Tom Livne to its board